Impact of statin therapy on systemic inflammation, left ventricular systolic and diastolic function and prognosis in low risk ischemic heart disease patients without history of congestive heart failure

Internal Medicine

Volumn 46, Issue 17, 2007, Pages 1337-1343

  Okura, Hiroyuki ^a   Asawa, Koichiro ^a   Kubo, Tomoichiro ^a   Taguchi, Haruyuki ^a   Toda, Iku ^a   Yoshiyama, Minoru ^b   Yoshikawa, Junichi ^c   Yoshida, Kiyoshi ^d  

^a Bell Land General Hospital   (Japan)

^b OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c Osaka Ekisaikai Hospital   (Japan)

^d KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

Heart failure; Hyperlipidemia; Ultrasonics

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM ANTAGONIST; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICORANDIL; NITRATE; CARDIOVASCULAR AGENT;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG USE; ECHOCARDIOGRAPHY; FEMALE; HEART DEATH; HEART LEFT ATRIUM; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HIGH RISK PATIENT; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PREDICTION; PROGNOSIS; PROTEIN BLOOD LEVEL; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; DIASTOLE; DRUG EFFECT; HEART MUSCLE ISCHEMIA; PATHOPHYSIOLOGY; SYSTOLE;

AGED; CARDIOVASCULAR AGENTS; DIASTOLE; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MYOCARDIAL ISCHEMIA; PROGNOSIS; SYSTOLE; VENTRICULAR FUNCTION, LEFT;

EID: 34548798144     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.46.0021     Document Type: Article

References (28)

1. Node K, Fujita. M, Kitakaze M, Hori M, Liao JK. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 108: 839-843, 2003.
2. Horwich TB, MacLellan WR, Fonarow GC. Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J Am Coll Cardiol 43: 642-648, 2004.
3. Mozaffarian D, Nye R, Levy WC. Statin therapy is associated with lower mortality among patients with severe heart failure. Am J Cardiol 93: 1124-1129, 2004.
4. Fukuta H, Sane DC, Brucks S, Little WC. Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. Circulation 112: 357-363, 2005.
5. Nagueh SF, Middleton KJ, Kopelen HA, et al. Doppler tissue imaging: a noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures. J Am Coll Cardiol 30: 1527-1533, 1997.
6. Ommen SR, Nishimura RA, Appleton CP, et al. Clinical utility of Doppler echocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures: A comparative simultaneous Doppler-catheterization study. Circulation 102: 1788-1794, 2000.
7. Dokainish H, Zoghbi WA, Lakkis NM, et al. Optimal noninvasive assessment of left ventricular filling pressures: a comparison of tissue Doppler echocardiography and B-type natriuretic peptide in patients with pulmonary artery catheters. Circulation 109: 2432-2439, 2004.
8. Hillis GS, Moller JE, Pellikka PA, et al. Noninvasive estimation of left ventricular filling pressure by E/e' is a powerful predictor of survival after acute myocardial infarction. J Am Coll Cardiol 43: 360-367, 2004.
9. Okura H, Takada Y, Kubo T, et al. Tissue doppler derived index of left ventricular filling pressure, E/E', predicts survival in patients with non-valvular atrial fibrillation. Heart 92: 1248-1252, 2006.
10. Serruys PW, de Feyter P, Macaya C, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 287: 3215-3222, 2002.
11. Takagi T, Yoshida K, Akasaka T, Hozumi T, Morioka S, Yoshikawa J. Intravascular ultrasound analysis of reduction in progression of coronary narrowing by treatment with pravastatin. Am J Cardiol 79: 1673-1676, 1997.
12. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291: 1071-1080, 2004.
13. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: The ASTEROID trial. JAMA 295: 1556-1565, 2006.
14. Vasan RS, Sullivan LM, Roubenoff R, et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation 107: 1486-1491, 2003.
15. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation 109: II2-10, 2004.
16. Anand IS, Latini R, Florea VG, et al. C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation 112: 1428-1434, 2005.
17. Mueller C, Laule-Kilian K, Christ A, et al. Inflammation and long-term mortality in acute congestive heart failure. Am Heart J 151: 845-850, 2006.
18. Sola S, Mir MQ, Rajagopalan S, et al. Statin therapy is associated with improved cardiovascular outcomes and levels of inflammatory markers in patients with heart failure. J Card Fail 11: 607-612, 2005.
19. Sola S, Mir MQ, Lerakis S, et al. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol 47: 332-337, 2006.
20. Albert MA, Danielson E, Rifai N, et al. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 286: 64-70, 2001.
21. Vaughan CJ, Murphy MB, Buckley BM. Statins do more than just lower cholesterol. Lancet 348: 1079-1082, 1996.
22. Tousoulis D, Antoniades C, Bosinakou E, et al. Effects of atorvastatin on reactive hyperemia and inflammatory process in patients with congestive heart failure. Atherosclerosis 178: 359-363, 2005.
23. Meyer B, Mortl D, Strecker K, et al. Flow-mediated vasodilation predicts outcome in patients with chronic heart failure: comparison with B-type natriuretic peptide. J Am Coll Cardiol 46: 1011-1018, 2005.
24. Takemoto M, Node K, Nakagami H, et al. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest 108: 1429-1437, 2001.
25. Hayashidani S, Tsutsui H, Shiomi T, et al. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 105, 868-873, 2002.
26. Bauersachs J, Galuppo P, Fraccarollo D, et al. Improvement of left ventricular remodeling and function by hydroxymethylglutaryl co-enzyme a reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation 104: 982-985, 2001.
27. Glorioso N, Troffa C, Filigheddu F, et al. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension 34: 1281-1286, 1999.
28. Ferrier KE, Muhlmann MH, Baguet JP, et al. Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. J Am Coll Cardiol 39: 1020-1025, 2002.